Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 placeSee list

Innovent Biologics Inc (1801)

Hong Kong
Currency in HKD
Disclaimer
48.85
+1.45(+3.06%)
Closed
1801 Scorecard
Full Analysis
Prominent player in the Biotechnology industry
Unusual trading volume
Fair Value
Day's Range
48.0049.95
52 wk Range
28.3052.15
Bid/Ask
48.85 / 48.85
Prev. Close
47.4
Open
48.1
Day's Range
48-49.95
52 wk Range
28.3-52.15
Volume
18,504,327
Average Volume (3m)
8,259,518
1-Year Change
10.15%
Fair Value
Unlock
Fair Value Upside
Unlock
1801 Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
53.12
Upside
+8.74%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year
Show more

Innovent Biologics Inc Company Profile

Innovent Biologics, Inc., a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor. The company is also developing IBI-326, a fully-human BCMA CAR T-cell therapy; IBI-376, an oral inhibitor of PI3Kd; IBI-351, a KRASG12C inhibitor; IBI-344, a repressor of silencing 1/TRK tyrosine kinase inhibitor; IBI-126, an ADC targeting CEACAM5; IBI-306, a novel anti-proprotein convertase subtilisin/kexin type 9 enzyme monoclonal antibody; IBI-362, a glucagon-like peptide-1 receptor/glucagon receptor dual agonist; and IBI-112, a novel long-acting anti-IL-23. In addition, it develops IBI-110, a novel anti-LAG3 monoclonal antibody; IBI-939, a novel anti-TIGIT monoclonal antibody; IBI-310, an anti-CTLA-4 monoclonal antibody; IBI-323, a novel LAG3/PD-L1 bispecific antibody; IBI-363, a potential PD-1/IL-2 bispecific antibody fusion protein; IBI-343, a recombinant anti-CLDN18.2 monoclonal ADC; and IBI-302, a potential anti-VEGF/complement bispecific fusion protein. Further, the company develops IBI-128, a late-stage novel non-purine xanthine oxidase inhibitor; IBI-353, a potent and selective, nextgeneration PDE4 inhibitor; and IBI-311, a recombinant anti-IGF-1R monoclonal antibody. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People’s Republic of China.

Employees
5294
Market
Hong Kong

Compare 1801 to Peers and Sector

Metrics to compare
1801
Peers
Sector
Relationship
P/E Ratio
−56.7x−8.4x−0.6x
PEG Ratio
−5.20−0.170.00
Price/Book
5.8x2.5x2.6x
Price / LTM Sales
9.7x7.6x3.2x
Upside (Analyst Target)
19.1%17.0%43.9%
Fair Value Upside
Unlock7.3%7.8%Unlock

FAQ

What Is the Innovent Biologics (1801) Stock Price Today?

The Innovent Biologics stock price today is 48.85

What Stock Exchange Does Innovent Biologics Trade On?

Innovent Biologics is listed and trades on the Hong Kong stock exchange.

What Is the Stock Symbol for Innovent Biologics?

The stock symbol for Innovent Biologics is "1801."

What Is the Innovent Biologics Market Cap?

As of today, Innovent Biologics market cap is 79.68B.

What is Innovent Biologics Earnings Per Share?

The Innovent Biologics EPS is -0.799.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.